Scarica l'app Stockscreener
12.00
2.65%
0.31
Dopo l'orario di chiusura:
12.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report? - Yahoo Finance
The Technical Signals Behind (KROS) That Institutions Follow - Stock Traders Daily
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? - msn.com
KROS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
[144] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock? - qz.com
Keros Therapeutics (KROS) awards 80,000 stock options to Chief Legal Officer - Stock Titan
Vanguard disaggregates holdings; reports 0 KROS shares (KROS) - Stock Titan
Fed Meeting: What are Keros Therapeutics Incs technical support levels2026 Dividend Review & Fast Gain Swing Alerts - baoquankhu1.vn
KROS stock: What to know about Rinvatercept in DMD - MSN
Chart Watch: What is Keros Therapeutics Incs P E ratio telling us2026 Year in Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Institution Moves: Can Keros Therapeutics Inc weather a recessionM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
Published on: 2026-03-25 15:00:50 - baoquankhu1.vn
KROS SEC FilingsKeros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics - Barchart.com
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from S&P Biotechnology Select Industry Index - MarketScreener
Precision Trading with Keros Therapeutics Inc. (KROS) Risk Zones - Stock Traders Daily
Quarterly Trades: Is now the right time to enter Keros Therapeutics Inc2026 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn
Block Trades: Will RIVN benefit from current market trendsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Can Keros Therapeutics Rinvatercept stand out in the DMD market? - MSN
Targets Report: Is Keros Therapeutics Inc likely to announce a buyback2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn
KROS: Does the Discounted Book Value Represent a Value Trap? - Bitget
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026 - sharewise.com
KROS Stock: Key Information on Rinvatercept for DMD - Bitget
KROS Pipeline Catalysts: DMD Phase II Progress and ALS Strategy for 2026 - Bitget
KROS Stock: What to Know About Rinvatercept in DMD - Yahoo Finance
KROS PE Ratio & Valuation, Is KROS Overvalued - Intellectia AI
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Hold" from Analysts - marketbeat.com
Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart
Myelofibrosis Market: Strong Pharma Growth Forecast Through - openPR.com
Keros Therapeutics (KROS) director submits initial Form 3 ownership - Stock Titan
Director adds Keros Therapeutics (NASDAQ: KROS) shares under 10b5-1 plan - Stock Titan
Technical Reactions to KROS Trends in Macro Strategies - Stock Traders Daily
Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL) - The Globe and Mail
Keros reports beneficial effects of RKER-065 in ALS model - bioworld.com
Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment - Minichart
Keros Therapeutics Advances Rinvatercept in ALS Collaboration - TipRanks
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - Bitget
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - The Manila Times
Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented - TradingView
Keros (NASDAQ: KROS) moves rinvatercept toward Phase 2 in ALS, DMD - Stock Titan
Keros Therapeutics Presents Additional Clinical Data from - GlobeNewswire
Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst - marketbeat.com
Sell Signal: Does Keros Therapeutics Inc stock reflect fundamentals2025 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? - The Globe and Mail
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Keros Therapeutics Inc vulnerable to short sellers2025 Price Targets & Weekly Sector Rotation Insights - baoquankhu1.vn
Can Keros Therapeutics Inc be the next market leaderM&A Rumor & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is Keros Therapeutics Inc. stock a buy before product launchesPortfolio Value Summary & Growth Focused Stock Reports - Naître et grandir
Keros Therapeutics, Inc. (KROS) reports Q4 loss, misses revenue estimates - MSN
Investment Review: Is now the right time to enter Keros Therapeutics IncChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Can Keros Therapeutics' Rinvatercept Distinguish Itself in the DMD Marketplace? - Bitget
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):